title: Advanced non-small cell lung cancer chemotherapy: a randomized trial of two active regimens (MVP and PE).
abstract: The treatment of advanced or metastatic NSCLC remains a controversial issue and cisplatin-based combination chemotherapy is by far the most common treatment. Two of these cisplatin-based standard combinations, MVP and PE, were compared in this study in order to evaluate their response rates and survival times. Eighty-five previously untreated NSCLC patients were randomly selected to receive either MVP or PE and 72 of these patients were eligible for evaluation for response rate and survival. Response rates for MVP were: CR 11%, PR 35%, SD 19% and PD 35% and for PE: CR 0%, PR 26%, SD 22% and PD 52%. The median survival time was 9.7 months for MVP and 6.9 months for PE. Both schedules were well tolerated. The administration of MVP in advanced NSCLC resulted in superior response rates and survival times over those produced by PE.
authors.affiliation: Department of Internal Medicine, Oncology Division, University of Patras Medical School, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Ginopoulos
authors.forename: K
authors.initials: K
authors.lastname: Spyropoulos
authors.forename: D
authors.initials: D
authors.lastname: Kardamakis
authors.forename: D
authors.initials: D
authors.lastname: Dougenis
authors.forename: A
authors.initials: A
authors.lastname: Onyenadum
authors.forename: C H
authors.initials: CH
authors.lastname: Gogos
authors.forename: E
authors.initials: E
authors.lastname: Solomou
authors.forename: K
authors.initials: K
authors.lastname: Chrysanthopoulos
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D016685:Mitomycin; D005047:Etoposide; D002945:Cisplatin; D014751:Vindesine